RACURA ONCOLOGY ORD
Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)
Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-quadruplexes, or G4s, which regulate many cancer-driving genes including the master switch MYC. Chief executive officer Dr Daniel Tillett […]
Race Oncology’s bisantrene RC220 AML treatment earns coveted FDA orphan drug designation
Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to the company’s acute myeloid leukemia (AML) candidate bisantrene RC220. The coveted designation qualifies Race for various benefits including tax credits, fee exemptions, market exclusivity and regulatory assistance from the FDA throughout the […]
Race Oncology heads into 2022 with extra $29.7m in bank to advance lead drug Zantrene
Race Oncology (ASX: RAC) is closing out 2021 with an extra $29.7 million in the bank after completing a heavily oversubscribed share purchase plan that saw almost $44 million in applications. Under the share purchase plan, eligible existing Race shareholders were offered the company’s stock at $3 each. The company has accepted $29.7 million of those […]
Published study highlights ‘superior efficacy’ of Race Oncology’s Zantrene combined with other cancer drugs
Race Oncology (ASX: RAC) has announced the publication of a peer-reviewed pre-clinical study that has identified additional drug combinations showing synergy with its cancer-fighting drug Zantrene when tested in acute myeloid leukaemia (AML) cells. The Race Oncology-sponsored paper entitled “Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukaemia […]
